Why NAD+ Is a Longevity Target
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell, essential for:
- Energy metabolism: Central electron carrier in glycolysis and oxidative phosphorylation
- Sirtuin activation: Sirtuins consume NAD+ as a substrate while performing DNA repair, stress response regulation, and metabolic optimization
- PARP activation: DNA repair enzymes that use NAD+
- cADPR synthesis: Involved in calcium signaling and circadian rhythm regulation
NAD+ levels decline by approximately 50% between youth and middle age, and further decline with aging. This decline impairs all NAD+-dependent processes — a reason researchers have become interested in NAD+ restoration as an anti-aging strategy.
The challenge: NAD+ cannot be absorbed intact from supplements. The body must synthesize it from precursors.
The Three Accessible Precursors
NMN (Nicotinamide Mononucleotide)
Position in pathway: One step away from NAD+ (NMN → NAD+ via NMN adenylyltransferase).
NMN is the most-hyped longevity supplement of the past decade, primarily due to David Sinclair's Harvard research and his personal use of it. Its popularity is larger than its clinical evidence base.
Human trial evidence:
- Imai et al. (Science, 2021): 250mg/day for 10 weeks in older men improved muscle insulin sensitivity and NAD+ levels
- Yoshino et al. (Science, 2021): 250mg/day in postmenopausal women with prediabetes improved muscle insulin signaling
- Yi et al. (GeroScience, 2023): 300mg/day for 60 days in healthy adults with elevated BMI improved sleep quality, fatigue, and cardiometabolic markers
Regulatory issue: In late 2022, the FDA issued notification that it considers NMN an investigational new drug (IND), which in theory removes it from the dietary supplement category. Enforcement has been inconsistent and products remain widely available, but the legal status is uncertain in the US.
Cost: High — typically $40–80+ per month for quality products
NR (Nicotinamide Riboside)
Position in pathway: Two steps from NAD+ (NR → NMN → NAD+).
NR has been commercially available longer than NMN and has a somewhat more developed human clinical trial base. The leading commercial form is Tru Niagen (Chromadex's patented Niagen NR).
Human trial evidence:
- Trammell et al. (Nature Communications, 2016): 250mg twice daily increased blood NAD+ by ~40–60%
- Dellinger et al. (Nature Metabolism, 2017): 100–300mg/day dose-dependently raised whole blood NAD+ metabolome
- Dollerup et al. (American Journal of Clinical Nutrition, 2018): 2g/day NR for 12 weeks raised NAD+ but showed no significant changes in insulin sensitivity or other metabolic endpoints in 40 healthy overweight men
- Martens et al. (Nature Communications, 2018): NR reduced arterial stiffness in older adults with elevated systolic blood pressure
Regulatory status: Recognized as a dietary supplement in the US (unlike NMN's contested status). Generally recognized as safe (GRAS) for food ingredient use at lower doses.
Cost: Moderate to high — typically $35–60/month
Niacin (Nicotinic Acid / Niacinamide)
Position in pathway: Multiple steps from NAD+ via the Preiss-Handler pathway (niacin) or salvage pathway (niacinamide/NAM).
Niacin is the oldest and cheapest of the three — it's been a recognized essential vitamin (B3) for a century and widely used in lipid management for decades.
Two forms:
- Nicotinic acid (niacin): Raises NAD+, lowers LDL, raises HDL — but causes flushing (prostaglandin-mediated cutaneous vasodilation) at doses effective for lipid management (typically 500–3,000mg)
- Niacinamide (nicotinamide/NAM): Raises NAD+, does not cause flushing — but inhibits sirtuins at high concentrations (a product of NAD+ metabolism that feeds back to inhibit the very enzymes longevity researchers are trying to activate)
Human evidence for NAD+ raising: Niacin is a proven, inexpensive NAD+ precursor. The question is whether its side effects and the sirtuin inhibition concern from niacinamide limit its longevity application.
A 2021 clinical trial (Peluso et al.) found high-dose niacinamide (1g/day) raised NAD+ in skeletal muscle — confirming its efficacy for the purpose.
Cost: Extremely low — pennies per day for pharmaceutical-grade niacin or niacinamide
Head-to-Head Comparison
| Property | NMN | NR | Nicotinic Acid | Niacinamide |
|---|---|---|---|---|
| Steps from NAD+ | 1 | 2 | Multiple | Multiple |
| Human trials raising NAD+ | Yes (multiple) | Yes (multiple) | Established | Yes |
| Human metabolic/health trials | Muscle insulin sensitivity (2021) | Mixed results | Decades of lipid research | Limited longevity-specific data |
| US regulatory status | Contested (IND notification) | Supplement (GRAS) | Supplement/drug (dose dependent) | Supplement |
| Flushing | No | No | Yes (often dose-limiting) | No |
| Sirtuin inhibition risk | Low | Low | Low at typical supplement doses | Potential at high doses |
| Cost per month | $40–80+ | $35–60 | $2–10 | $3–15 |
| Longevity animal data | Extensive mouse data | Moderate mouse data | Less longevity focus | Less longevity focus |
The Practical Question: Which Should You Take?
The honest answer is that there is no clear winner based on current human evidence. The field is moving fast but the clinical endpoint data (actual longevity outcomes, disease prevention) doesn't exist yet for any of these compounds.
If cost is a consideration: Niacinamide is the most economical way to raise NAD+. The sirtuin inhibition concern at very high doses may be worth monitoring, though at typical doses this may be a theoretical concern more than a demonstrated problem.
If you want the compounds used in the primary longevity research: NMN (if regulatory status doesn't concern you) or NR (clearer supplement status, substantial evidence base).
If you have cardiovascular concerns: Niacin (nicotinic acid) has decades of human cardiovascular data and inexpensively raises HDL while lowering triglycerides — though the flush is a significant tolerability barrier for many people.
Practical perspective: The best-supported interventions for maintaining NAD+ levels and sirtuin activity may not be supplements at all. Fasting, caloric restriction, and exercise all raise NAD+ and SIRT1 activity through AMPK activation and other pathways — with robust human evidence for metabolic and health benefits. Supplements may be useful adjuncts but lifestyle optimization likely has larger effect sizes.
Related: NMN and NAD+: Aging Biology and What Current Studies Show · Urolithin A vs. Fisetin vs. Spermidine: 2026 · Vitamin D Dosage Calculator
Be the first to try Prova
We're building an app to track whether NAD+ and longevity actually works. Join the waitlist.